4-CN-BINACA-ADB is a recently developed synthetic cannabinoid. It is a member of the cannabinoid family, specifically a type of indazole-3-carboxamide indazole. It is closely linked to a series of such compounds developed by Pfizer in 2009. These were originally in development as painkillers. Like most synthetic indazole cannabinoids, this is a potent CB1 agonist. The 4-CN-BINACA-ADB is not approved as a drug, supplement or treatment in any known jurisdiction. It is only for research chemical purpose, and should never be taken by humans, or used for any kind of chemical in vivo research. 4-CN-BINACA-ADB is sold for in vitro experimentation or for sample calibration purposes only.